Effect of Withdrawal of Pravastatin Therapy on C-Reactive Protein and Low-Density Lipoprotein Cholesterol

American Journal of Cardiology

Volumn 100, Issue 10, 2007, Pages 1548-1551

  van der Harst, Pim ^a   Asselbergs, Folkert W ^a   Hillege, Hans L ^a   Bakker, Stephan J L ^a   Voors, Adriaan A ^a   van Veldhuisen, Dirk J ^a   van Gilst, Wiek H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REBOUND; SMOKING;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES;

EID: 35748979461     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.06.054     Document Type: Article

References (25)

1. Asselbergs F.W., Diercks G.F., Hillege H.L., van Boven A.J., Janssen W.M., Voors A.A., de Zeeuw D., de Jong P.E., van Veldhuisen D.J., and van Gilst W.H. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110 (2004) 2809-2816
2. van der Harst P., Voors A.A., Volbeda M., Buikema H., van Veldhuisen D.J., and van Gilst W.H. Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. Am J Cardiol 97 (2006) 1697-1701
3. van der Harst P., Asselbergs F.W., Buikema H., Voors A.A., van Veldhuisen D.J., and van Gilst W.H. Effects of C-reactive protein and cholesterol on responsiveness in vitro of the internal thoracic artery to angiotensin II in patients having coronary artery bypass grafting. Am J Cardiol 98 (2006) 751-753
4. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100 (1999) 230-235
5. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., and Braunwald E. the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction. C-Reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
6. Lee K.T., Lai W.T., Chu C.S., Tsai L.Y., Yen H.W., Voon W.C., and Sheu S.H. Effect of withdrawal of statin on C-reactive protein. Cardiology 102 (2004) 166-170
7. Yip H.K., Youssef A.A., Chua S., Hung W.C., Chen Y.H., Yeh K.H., Wu C.J., and Hang C.L. Re-elevation of high-sensitivity C-reactive protein but not the von Willebrand factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting. Int Heart J 47 (2006) 501-509
8. Huang C.Y., Wu T.C., Lin W.T., Leu H.B., Lin C.P., Lin S.J., and Chen J.W. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. Eur J Clin Invest 36 (2006) 76-84
9. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., Grines C.L., and DeMaria A.N. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
10. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
11. van der Harst P., Voors A.A., van Gilst W.H., Bohm M., and van Veldhuisen D.J. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 71 (2006) 443-454
12. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., and Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
13. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
14. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., and Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98 (1998) 839-844
15. Buffon A., Liuzzo G., Biasucci L.M., Pasqualetti P., Ramazzotti V., Rebuzzi A.G., Crea F., and Maseri A. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 34 (1999) 1512-1521
16. Walter D.H., Fichtlscherer S., Sellwig M., Auch-Schwelk W., Schachinger V., and Zeiher A.M. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 37 (2001) 839-846
17. Brouilette S.W., Moore J.S., McMahon A.D., Thompson J.R., Ford I., Shepherd J., Packard C.J., and Samani N.J. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369 (2007) 107-114
18. van der Harst P., van der Steege G., De Boer R.A., Voors A.A., Hall A.S., Mulder M.J., van Gilst W.H., van Veldhuisen D.J., and MERIT-HF Study Group. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol 49 (2007) 1459-1464
19. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., and Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
20. Blackburn D.F., Dobson R.T., Blackburn J.L., Wilson T.W., Stang M.R., and Semchuk W.M. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 21 (2005) 485-488
21. Eagle K.A., Kline-Rogers E., Goodman S.G., Gurfinkel E.P., Avezum A., Flather M.D., Granger C.B., Erickson S., White K., and Steg P.G. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 117 (2004) 73-81
22. Jackevicius C.A., Mamdani M., and Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002) 462-467
23. Spencer F.A., Fonarow G.C., Frederick P.D., Wright R.S., Every N., Goldberg R.J., Gore J.M., Dong W., Becker R.C., and French W. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med 164 (2004) 2162-2168
24. Fonarow G.C., Wright R.S., Spencer F.A., Fredrick P.D., Dong W., Every N., and French W.J. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96 (2005) 611-616
25. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497